Obesity

Disease State Hub

Videos

ADHD

Nicotinamide Riboside Activates Protective Sirtuin Enzymes

10/24/2019

Charles Brenner, PhD, director of the Obesity Initiative at the University of Iowa, discusses properties of nicotinamide riboside that have been uncovered since its initial discovery in 2004.

10/24/2019

Research Summaries

Conference Coverage

Is There an Association Between Semaglutide Usage and Additional Surgical Interventions Following Transforaminal Lumbar Interbody Fusion?

05/22/2024

Anthony Calabro, MA

Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.

05/22/2024

Research summary

Gastric Bypass Surgery Improves Continued Type 2 Diabetes Remission, Even After Weight Recurrence

03/22/2024

Jessica Ganga

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

03/22/2024

FDA Alert

FDA Approves Semaglutide For Reducing Serious Cardiovascular Events Among Adults With Heart Disease and Obesity, Overweight

03/21/2024

Anthony Calabro, MA

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

03/21/2024

Research Summary

Research Summary

Late-Stage Persistence With Anti-Obesity Medication Varies By Medication, Weight Loss At 6 Months

02/14/2024

Jessica Ganga

Researchers evaluated the early- and later-stage use of various anti-obesity medications in patients.

02/14/2024

Research Summary

Semaglutide Provides Benefits for Patients With HFpEF and Obesity

11/22/2023

Anthony Calabro, MA

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

11/22/2023

October 2024

Current Issue

October 2024

Volume 64

Issue 9